Adicet Bio, Inc.
ACET
Price:
$1.48
Market Cap:
$121.95M
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is base...[Read more]
Industry
Biotechnology
IPO Date
2018-01-26
Stock Exchange
NASDAQ
Ticker
ACET
The ROE as of September 2024 (TTM) for Adicet Bio, Inc. (ACET) is -63.95%
According to Adicet Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -63.95%. This represents a change of 284.67% compared to the average of -16.62% of the last 4 quarters.
Adicet Bio, Inc. (ACET) Historical ROE (quarterly & annually)
How has ACET ROE performed in the past?
The mean historical ROE of Adicet Bio, Inc. over the last ten years is 0.63%. The current -63.95% ROE has changed -10205.83% with respect to the historical average. Over the past ten years (40 quarters), ACET's ROE was at its highest in in the December 2017 quarter at 200.94%. The ROE was at its lowest in in the March 2019 quarter at -90.75%.
Average
0.63%
Median
10.48%
Minimum
-83.83%
Maximum
46.61%
Adicet Bio, Inc. (ACET) ROE by Quarter and Year
Discovering the peaks and valleys of Adicet Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 20.69%
Maximum Annual ROE = 46.61%
Minimum Annual Increase = -622.33%
Minimum Annual ROE = -83.83%
| Year | ROE | Change |
|---|---|---|
| 2023 | -83.83% | -397.80% |
| 2022 | 28.15% | -23.57% |
| 2021 | 36.83% | 6.77% |
| 2020 | 34.50% | -25.99% |
| 2019 | 46.61% | -622.33% |
| 2018 | -8.92% | -86.87% |
| 2017 | -67.98% | 20.69% |
| 2016 | -0.00% | -100.00% |
| 2015 | 11.41% | 19.34% |
| 2014 | 9.56% | -16.67% |
Adicet Bio, Inc. (ACET) Average ROE
How has ACET ROE performed in the past?
The current ROE of Adicet Bio, Inc. (ACET) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-6.28%
5-year avg
12.45%
10-year avg
0.63%
Adicet Bio, Inc. (ACET) ROE vs. Peers
How is ACET’s ROE compared to its peers?
Adicet Bio, Inc.’s ROE is greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Talaris Therapeutics, Inc. (-36.43%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Vor Biopharma Inc. (-86.42%), greater than Tenaya Therapeutics, Inc. (-80.97%), greater than Bicycle Therapeutics plc (-32.80%), greater than IGM Biosciences, Inc. (-119.02%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than Homology Medicines, Inc. (-100.91%), greater than Nkarta, Inc. (-28.83%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Alector, Inc. (-102.63%), greater than Aadi Bioscience, Inc. (-66.67%), greater than Keros Therapeutics, Inc. (-44.73%),
| Company | ROE | Market cap |
|---|---|---|
| -28.01% | $1.64B | |
| -36.43% | $116.44M | |
| -28.37% | $1.04B | |
| -86.42% | $62.11M | |
| -80.97% | $182.23M | |
| -32.80% | $1.42B | |
| -119.02% | $552.26M | |
| -70.40% | $349.21M | |
| -57.89% | $773.92M | |
| -83.65% | $54.85M | |
| -47.31% | $250.26M | |
| -122.97% | $46.68M | |
| -47.05% | $2.46B | |
| -100.91% | $3.02M | |
| -28.83% | $375.37M | |
| -41.05% | $782.51M | |
| -102.63% | $472.01M | |
| -66.67% | $45.05M | |
| -44.73% | $1.97B |
Build a custom stock screener for Adicet Bio, Inc. (ACET) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adicet Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Adicet Bio, Inc. (ACET) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Adicet Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Adicet Bio, Inc.'s ROE?
How is the ROE calculated for Adicet Bio, Inc. (ACET)?
What is the highest ROE for Adicet Bio, Inc. (ACET)?
What is the 3-year average ROE for Adicet Bio, Inc. (ACET)?
What is the 5-year average ROE for Adicet Bio, Inc. (ACET)?
How does the current ROE for Adicet Bio, Inc. (ACET) compare to its historical average?